Clinical Trial Update: Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel with or without OGX-427 in relapsed/refractory metastatic bladder cancer; study completed with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• OGX-427 (apatorsen)

Snippet

Sponsor: Noah Hahn, M.D. | Conditions: Bladder Cancer, Urothelial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-11-14